

Bertrand price competition with substance preferences in insurance markets*

Veronika Varga

Corvinus University of Budapest

Online International Conference in Actuarial Science, Data
Science and Finance
28 April 2020

*joint work with Kolos Ágoston



Is the larger substance preferred?

- Substance with independent and homogenous risks
- Solvency II – Value at Risk
- If X and Y are normally distributed, VaR is subadditive
$$VaR_{99.5\%}(X + Y) \leq VaR_{99.5\%}(X) + VaR_{99.5\%}(Y)$$
- Can be a motivation to increase the substance
- It may be worth examining the question from a decision theory perspective

Insurance market

Oligopoly vs Perfect competition

- **Turkey:** Kasman – Turgutlu (2008)
- **Netherlands:** J. A. Bikker – M. van Leuvensteijn (2011)
- **Sweden:** Lindmark – Andersson – Adams (2006)
- **Taiwan:** Wang – Tzeng - Wang (2003)
- **Central and Eastern Europe:** Tipurić – Pejić Bach – Pavić (2008)

Most cases seem to support the oligopoly model.

Oligopolies in insurance market

- Bertrand oligopoly – Bertrand paradoxon
- Sonnenholzner and Wambach (2004), Polborn (1998), Wambach (1999) – oligopoly models with positive profit in insurance market
- Villas-Boas and Schmidt-Mohr (1999) – asymmetric information and product differentiation in credit markets

The model

I : number of the insurers

- with the same utility function, u
- with the same wealth, w_0

N : number of the potential customers

- $D(p)$: the probability that a customer will buy at p
- Each customer faces the risk to lose K in an accident with probability q

The model

- Bertrand competition
- The firm that quotes the lowest premium sells to all consumers
- If several insurers quote the same lowest premium, they share the market equally
- $D(p) = \frac{\bar{K}-p}{\bar{K}-qK}$, where \bar{K} is a fixed parameter

Substance preference

The indifferent price

Let $P_n(q, K)$ be the price, when the insurer company is indifferent to do not sell any contracts or to sell n contracts.

$$U(w, P_n(q, K), n, q, K) = u(w)$$

Substance preference

We say, that u utility function is **substance averse**, iff

$$U(w, P_n(q, K), n + 1, q, K) < U(w, P_n(q, K), n, q, K) , \\ \forall n \in \mathcal{Z}^+, q \in (0, 1), K \in \mathcal{R}^+ . \quad (1)$$

If in (1) there is equality, than the utility function is **substance neutral**, if there is greater relation, than it is **substance seeking**.

Substance neutral

The exponential utility function is substance neutral

- $u(w) = -e^{-rw}$, where $r > 0$


The indifferent price is independent of n

- $P_n(q, K) = \frac{1}{r} \ln(qe^{rK} + (1 - q))$

What happens in the market equilibrium?

- No extra utility is available in equilibrium

Indifference curves – Substance neutral case



Substance aversion


The mixed exponential utility function and the quadratic utility function are substance averse utility functions

- $u(w) = aw - \exp(-rw)$
- $u(w) = w - bw^2$, $b > 0$, $w \leq \frac{1}{2b}$

What happens in the market equilibrium?

- positive extra utility is available
- asymmetry in the market is possible


Indifference curves – Substance averse case



Substance seeking

$$u(w) = \begin{cases} 300[-\exp(-1 - \frac{x - 100}{140}) + \exp(-1) + \frac{x - 100}{1000000}], \\ \text{if } x \leq 100 \\ \\ 750[-\exp(-1 - \frac{x - 100}{500}) + \exp(-1) + \frac{x - 100}{1000000}], \\ \text{if } x > 100 \end{cases} \quad (2)$$

Indifference curves – Substance seeking case



Proper risk aversion

An undesirable lottery can never be made desirable by the presence of an independent, undesirable lottery (Pratt and Zeckhauser 1987).

Proper risk aversion

Let W , M , L be independent risks. If the u utility function has the proper risk aversion property, then

if

$$Eu(W + L) \leq Eu(W)$$

and

$$Eu(W + M) \leq Eu(W)$$

then

$$Eu(W + L + M) \leq Eu(W + M)$$



Conclusion and further research questions

- 1 Connection between substance preference and the risk attitude
 - Proper risk aversion usually leads to substance aversion
 - But substance aversion is a more general concept
 - Substance seeking example is an improper utility function
- 2 Market equilibrium
 - Substance neutral case – no extra utility
 - Substance aversion – extra utility, no unique equilibrium
 - Substance seeking – monopol situation
- 3 How general are our findings?

Thank you for your attention!

Sources

J. A. Bikker and M. van Leuvensteijn (2011) : *Competition and efficiency in the Dutch life insurance industry*, Applied Economics, 40:16, 2063-2084 2011

Adnan Kasman, Evrim Turgutlu (2008): *Competitive Conditions in the Turkish Non– Life Insurance Industry*, Review of Middle East Economics and Finance, Volume 4, Number 1 2008 Article 5

Magnus Lindmark , Lars-Fredrik Andersson and Mike Adams (2006): *The Evolution and Development of the Swedish Insurance Market*, Accounting, Business & Financial History, 16:3, 341-370

Polborn, M. K. (1998): *A Model of an Oligopoly in an Insurance Market*, The Geneva Papers on Risk and Insurance Theory, 23, 41–48.

Pratt, J. W. (1964): *Risk aversion in the small and in the large*, Econometrica 32, 122–136.

Pratt, J. W. and Zeckhauser, R. J. (1987): *Proper Risk Aversion*, Econometrica, 55(1), 143–154.

Sources

Sonnenholzner, M. and Wambach, A. (2004): *Oligopoly in Insurance Markets*, In: Teugels, J. és Sundt, B. (eds). *Encyclopedia of Actuarial Science*. Wiley, Chichester, UK (2004)

Darko Tipurić , Mirjana Pejić Bach and Tomislava Pavić (2008): *Concentration of the insurance industry in selected transition countries of Central and Eastern Europe, 1998-2006*, 2008 *Post-Communist Economies*, 20:1, 97-118

J. Miguel Villas-Boas and Udo Schmidt-Mohr (1999): *Oligopoly with Asymmetric Information: Differentiation in Credit Markets*, *The RAND Journal of Economics*, Vol. 30, No. 3 (Autumn, 1999), pp. 375-396

Jennifer L. Wang, Larry Y. Tzeng and En-Lin Wang (2003): *The Nightmare of the Leader: The Impact of Deregulation on an Oligopoly Insurance Market*, *Source: Journal of Insurance Issues*, Vol. 26, No. 1 (SPRING 2003), pp. 15-28

Wambach, A. (1999): *Bertrand competition under cost uncertainty*, *International Journal of Industrial Organization*, 17, 941–951.

Risk attitude

Risk Aversion

An agent is risk averse if his or her utility function is concave.

Absolute Risk Aversion

A common measure of absolute risk aversion is the following:

$$r(x) = \frac{-u''(x)}{u'(x)} \text{ (Pratt, 1964).}$$

If $r(x)$ is increasing then u is called Increasing Risk Aversion utility function (IARA).

If $r(x)$ is decreasing then u is called Decreasing Risk Aversion utility function (DARA).

If $r(x)$ is constant then u is called Constant Risk Aversion utility function (CARA).

Proper risk aversion - Gollier and Pratt example

$$u(x) = \begin{cases} x & \text{if } x < 100 \\ 50 + \frac{x}{2} & \text{if } x \geq 100 \end{cases}$$

$w_0 = 101$ so $u(w_0) = 100.5$

1. risk 50% $w_1 = 90$ and 50% $w_1 = 115$

2. risk 50% $w_2 = 81$ and 50% $w_2 = 121$

$Eu(1.risk) = 0.5u(90) + 0.5u(115) = 98.75$ so $Eu(1.risk) < u(w_0)$

1.risk is not preferred

$Eu(2.risk) = 0.5u(81) + 0.5u(121) = 95.75$ so $Eu(2.risk) < u(w_0)$

2. risk is not preferred

but $Eu(1.risk + 2.risk) = 96.875 > Eu(2.risk)$

Substance aversion: DARA - Proper risk aversion

If $Eu(W + L) \leq Eu(W)$ and $Eu(W + M) \leq Eu(W)$
then $Eu(W + L + M) \leq Eu(W + M)$.

$$W * L * M \preceq W * M \sim W$$

Examples for proper risk aversion DARA case
The indifferent price increasing in N - The case of substance aversion

Utility function	N = 1	N = 2	N = 3	N = 5	N = 10
$\ln(x)$	1.052991	1.052996	1.053002	1.053012	1.053039
\sqrt{x}	1.026043	1.026045	1.026047	1.026051	1.026062
$x - \frac{e^{-x/10}}{1000}$	0.121747	0.346822	2.201726	9.789496	18.2315